retatrutide weight loss phase 2 trial obesity triple agonist First-in-Class 'Triple-G'! Retatrutide, a first-in triple agonist Archives - Drug

Russo L, Andreozzi P, Zito FP, Vozzella L, Savino IG, Sarnelli G, Cuomo R

When to Seek Medical Care for Cold Symptoms and Complications Most people recover from colds without incident, but complications requiring medical care (such as sinus or ear infections or acute bronchitis) are possible

Recent studies have reported that the development of heart failure in adolescents is closely associated with a dramatic increase in DM, obesity, and metabolic dysfunction-associated steatotic liver disease (MASLD) (Wu et al., 2024

Diamond LE et al

For instance, in clinical trials, Retatrutide achieved up to a 24.2% reduction in body weight over 48 weeks, whereas Tirzepatide users saw an average weight loss of 19.5% and 20.9% after 72 weeks of treatment (10-mg and 15-mg dose, respectively)

And whether co-strategiessuch as microbiome-modifying diets or targeted probioticscan reduce TMAO production while preserving benefits is an active research area